At the European Cancer Congress (ECC) 2015, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute UK, London, UK, discusses a phase 1b clinical trial that evaluated the safety and clinical activity of avelumab, a fully human anti-PD-L1 IgG1 antibody, for the treatment of patients with locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.
Phase 1b trial of avelumab in advanced gastric or gastroesophageal junction cancer
14th October 2015
Join our mailing list
To receive the EMJ updates straight to your inbox free of charge, please click the button below.Join Now